You are not allowed to view Ad
News View all news
FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
FDA has approved patisiran (Onpattro—Alnylam Pharmaceuticals) infusion for the treatment of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This is the first FDA-approved treatment for individuals with polyneuropathy caused by hATTR.
Analysis of NDMA levels in recalled valsartan in the U.S.
FDA on Friday said it "wanted to put some context around the actual potential risk posed to patients who used versions of valsartan that may have contained high levels of NDMA." The agency announced on July 13 a recall of particular batches of valsartan tablets due to an impurity, the chemical N-nitrosodimethylamine (NDMA).
FDA approves targeted treatment for patients with relapsed or refractory AML who have a certain genetic mutation
FDA approved on Friday ivosidenib (Tibsovo—Agios Pharmaceuticals) tablets for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a particular genetic mutation. The drug is approved for use with an FDA companion diagnostic used to identify specific mutations in the IDH1 gene in patients who have AML.
FDA approves the first drug with an indication for treatment of smallpox
FDA has approved tecovirimat (TPOXX—SIGA Technologies Inc.), the first drug with an indication for treatment of smallpox, the agency said Friday. The World Health Organization declared smallpox eradicated in 1980; however, there is concern that it could be used as a potential bioweapon.
April 3, 2018
Keep making noise about how pharmacists are fighting the opioid…
We asked, and you delivered. THANK YOU! APhA has been on social media and pharmacist.com rallying the troops to contact their representatives in Congress and tell them that to make a meaningful…0 comments
May 15, 2018
Test - XXX
The Speaker-elect serves a one-year term in that capacity before taking over as Speaker of the House and Trustee for two years. The entire term for this position is three years, beginning the day after the close of the 2018 APhA Annual Meeting and concluding on the last day of the 2021 APhA Annual Meeting.
The Speaker-elect serves a one-year term in that capacity before taking over as Speaker of the House and Trustee for two years
APhA is the leading advocate for the pharmacy profession and a driving force in creating opportunities for pharmacists to play a key role in integrated patient care, and ensuring the profession is recognized as essential in optimal medication use. We strive to make your job as a pharmacist easier, by providing the latest industry news, continuing education and professional development opportunities, practice tools, and more, so that you can focus on caring for your patients.